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our study aimed to explore the association between serum c-reactive protein (cRp) and post-stroke 
depressive symptoms. We prospectively recruited 572 patients with ischemic stroke or transient 
ischemic attack in whom serum CRP level was measured within 48 h after stroke onset. Depressive 
symptoms were assessed at day 8 and 3 months after stroke in 405 and 306 patients, respectively. 
Patients with greater depressive symptoms at day 8 and patients with greater depressive symptoms 
3 months after stroke had higher CRP level (median: 7.9 vs 4.3 mg/L, P < 0.01 and 6.7 vs 3.4 mg/L, 
p = 0.01, respectively). In the univariate analysis, CRP > 9.2 mg/L was associated with depressive 
symptoms at day 8 (OR: 2.06, 95%CI: 1.30–3.28, P < 0.01) and CRP > 4.3 mg/L was associated with 
depressive symptoms 3 months after stroke (OR: 1.79, 95%CI: 1.06–3.02, P = 0.03). In the multivariate 
analysis, higher CRP level was related to depressive symptoms at day 8 (OR: 2.23, 95%CI: 1.28–3.90, 
p < 0.01), but not depressive symptoms 3 months after stroke (OR: 1.13, 95%CI: 0.59–2.17, P = 0.71). In 
conclusion, higher levels of CRP are associated with greater depressive symptoms at day 8 after stroke, 
but their effects on depressive symptoms 3 months after stroke are less significant.
Mounting evidence indicates that peripheral inflammation might contribute to the pathophysiology of major 
depressive disorder (MDD)1–3. Animal studies demonstrate that systemic inflammation might interact with the 
mechanisms important for depression such as, neurotransmitter metabolism, glucocorticoid receptor resist-
ance, and neuronal plasticity4. Clinical studies show that circulating markers of immune activation, including 
cytokines, chemokines, and acute-phase proteins, are observed in the blood of individuals with MDD. The 
most replicated findings, confirmed by several meta-analyses, pertain to raised C-reactive protein (CRP) and 
interleukin-6 in a subset of MDD patients5–8.
About 30% of patients develop depression at any time point up to 5 years after stroke9,10. Post-stroke depres-
sion is associated with worse functional outcome and increased mortality11.
In contrast to MDD, the role of systemic inflammation in the pathobiology of post-stroke depression is not 
well defined. Systemic inflammatory reaction accompanies ischemic stroke. This reaction includes two compo-
nents: low-grade inflammation that is related to stroke risk factors and comorbidities (e.g. atherosclerosis, hyper-
tension, diabetes mellitus, heart failure or ischemic heart disease) and acute-phase reaction triggered by brain 
injury and exacerbated by post-stroke infections. As a result, blood levels of interleukin-6 and CRP rise during 
the first few days after stroke onset12. Since post-stroke systemic inflammation could be a potential therapeutic 
target13, a better understanding of relationships between peripheral inflammation and depression is clinically 
important.
Our study aimed to explore the association between circulating CRP and post-stroke depressive symptoms.
Methods
patient selection and clinical assessment. Patients recruited to this study were selected from persons 
who participated in the PROPOLIS study (PRospective Observational POLIsh Study on post-stroke delirium). 
PROPOLIS was a prospective study conducted in the Department of Neurology, University Hospital, Krakow, 
Poland14. The main aim of the PROPOLIS was to determine the frequency, risk factors and prognosis of post-
stroke delirium. Participants were recruited to this study between May 2014 and March 2016.
The inclusion criteria to the current sub-study on depressive symptoms were: (1) ischemic stroke or transient 
ischemic attack (TIA); (2) serum CRP measurement within 48 h after stroke onset; and (3) informed patient’s 
consent. The exclusion criteria were: (1) the pre-stroke diagnosis of major depressive disorder (retrieved from 
medical records) and (2) hemorrhagic stroke.
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The Bioethics Committee of Jagiellonian University approved the study’s protocol. Each patient gave informed 
consent. All methods were performed in accordance with approved guidelines and regulations.
The presence of depressive symptoms was assessed at day 8 ± 1 and 3 months after stroke onset using the 
Patient Health Questionnaire (PHQ-9)15,16. Previous studies showed that PHQ-9 is a valid and clinically feasible 
depression screening tool for stroke17. Score ≥10 was considered indicative of greater depressive symptoms18,19. 
The PHQ-9 was administrated face-to-face by a trained neurologist or psychologist. Before the PHQ-9 adminis-
tration, aphasia was examined using clinical methods that assessed speech fluency and content, comprehension, 
and naming. Patients who were not able to understand questions were excluded from the study.
The Neuropsychiatric Inventory (NPI) was used to assess neuropsychiatric disturbances occurring within the 
4 weeks before admission. The NPI-Q10 subscale includes 10 behavioural items: delusions, hallucinations, agita-
tion, depression, anxiety, euphoria, apathy, disinhibition, irritability, and aberrant motor behaviour20,21. A score 
for each item (from zero to 12) is a product of severity scale (from zero to 3) and frequency scale (from zero to 4).
The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) with a cut-off of 3.3 was used to 
diagnose a pre-stroke cognitive decline22,23. The IQCODE consists of 26 items that rate change in patients’ intel-
lectual abilities over the past 10 years24.
The core features of delirium were examined using the Brief Confusion Assessment Method25.
National Institute of Health Stroke Scale (NIHSS) was used to assess neurological deficit on admission26. A 
score of zero means normal function and higher scores indicate greater impairment. The total score ranges from 
zero to 42.
Laboratory assays. Serum CRP level was quantified via the immunoturbidometric method (Roche 
Diagnostics, Mannheim, Germany). The assay detection limit was 1 mg/L.
Statistical analysis. The χ2 test was used to compare proportions, while the Mann–Whitney U-test was 
used to compare continuous variables between groups. Logistic regression was used to determine the predictors 
of functional outcome. Variables with P < 0.05 in the univariate analysis were included in a multivariate analysis. 
The Box-Tidwell test was used to check the linearity of the logit for the continuous independent variables in logis-
tic regression analysis. The receiver operating characteristic curves were used to identify an optimal cut-off level 
of CRP that differentiates patients with greater depressive symptoms from those with lower depressive symptoms. 
Since CRP level could raise within 48 h after stroke onset and its level measured within 12 h might be lower than 
its level measured between 24–48 h12, two sensitivity analyses were performed. In the first, the patients in whom 
the CRP level was measured within 12 h after stroke were excluded. In the second analysis, only patients with 
CRP measurement within 24 h after stroke were included. The calculations were performed using the program 
STATISTICA for Windows (version 12.5, Statsoft, Poland).
Results
Of 750 patients that participated in the PROPOLIS study, 572 patients had an ischemic stroke or TIA and the 
CRP measurement within 48 h after stroke onset. After the exclusion of patients who died or were not able to 
perform PHQ-9, depressive symptoms were assessed in 405 patients at day 8 and in 306 patients 3 months after 
stroke (Fig. 1).
Depressive symptoms at day 8. Of 405 included patients (median age: 70, IQs: 61–80; 51.6% women; 
median NIHSS: 4, IQs: 2–9), greater depressive symptoms were diagnosed in 104 patients (25.7%).
Compared to patients with lower depressive symptoms, patients with greater depressive symptoms were more 
often women; suffered from hypertension, previous stroke, and pre-stroke cognitive decline; took antidepressants 
before index stroke; and had higher pre-stroke NPI score (Table 1). Serum CRP level was higher in patients with 
greater depressive symptoms.
In the univariate analysis, CRP level above 9.2 mg/L was associated with greater depressive symptoms (OR: 
2.06, 95%CI: 1.30–3.28, P < 0.01). In the multivariate analysis adjusted for hypertension, female sex, previ-
ous stroke, pre-stroke cognitive decline, the use of anti-depressant before stroke, and the NPI score, CRP level 
remained the independent predictor of depression (OR: 2.23, 95%CI: 1.28–3.90, P < 0.01). Other independent 
predictors of greater depressive symptoms were: female sex (OR: 2.97, 95%CI: 1.67–5.29, P < 0.01), previous 
stroke (OR: 2.08, 95%CI: 1.08–4.01, P = 0.03), the NPI score (OR: 1.05, 95%CI: 1.02–1.08, P < 0.01) and the use 
of anti-depressant before stroke (OR: 6.07, 95%CI: 1.14–32.17, P = 0.03).
Depressive symptoms 3 months after stroke onset. Of 306 included patients (median age: 69, IQs: 
61–79; 50.6% women; median NIHSS: 4, IQs: 2–8), greater depressive symptoms were diagnosed in 82 patients 
(26.8%).
Compared to patients with lower depressive symptoms, patients with greater depressive symptoms more often 
suffered from hypertension, diabetes mellitus, and post-stroke delirium; took antidepressants during 3 months 
after stroke onset; and had higher pre-stroke NPI score (Table 2). Serum CRP level was higher in patients with 
greater depressive symptoms.
In the univariate analysis, CRP level above 4.3 mg/L was associated with greater depressive symptoms (OR: 
1.79, 95%CI: 1.06–3.02, P = 0.03). This association was nonsignificant in the multivariate analysis adjusted for 
hypertension, diabetes mellitus, delirium, the use of antidepressant and the NPI score (OR: 1.13, 95%CI: 0.59–
2.17, P = 0.71). The independent predictors of greater depressive symptoms in this model were: hypertension 
(OR: 2.81, 95%CI: 1.27–6.20, P = 0.01), diabetes mellitus (OR: 2.13, 95%CI: 1.08–4.19, P = 0.03), and the use of 
antidepressant (OR: 4.36, 95%CI: 1.96–9.69, P < 0.01).
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When patients treated with anti-depressants were excluded from the analysis, CRP was still associated with 
depressive symptoms in the univariate (OR: 2.00, 95%CI: 1.10–3.62, P = 0.02), but not in the multivariate analysis 
(OR: 1.04, 95%CI: 0.50–2.16, P = 0.92).
Sensitivity analysis. In the first sub-analysis, we excluded patients in whom serum CRP level was measured 
within 12 h after stroke onset (N = 113). Compared to patients with lower depressive symptoms, patients with 
greater depressive symptoms at day 8 (median: 7.6, interquartiles: 2.1–25.5 mg/L vs median: 4.6, interquartiles: 
1.9–11.2 mg/L, P = 0.02) and patients with greater depressive symptoms 3 months after stroke (median: 6.7, inter-
quartiles: 2.7–19.1 mg/L vs median: 3.7, interquartiles: 1.6–11.1 mg/L, P = 0.02) had higher CRP level. In the uni-
variate analysis, serum CRP level above 19.0 mg/L was associated with higher depressive symptoms at day 8 (OR: 
2.45, 95%CI: 1.50–4.00, P < 0.01). Similarly, serum CRP level above 4.3 mg/L was related to higher depressive 
symptoms 3 months after stroke (OR: 2.14, 95%CI: 1.33–3.44, P < 0.01). In the multivariate analysis, higher CRP 
level remained an independent predictor of depressive symptoms at day 8 (OR: 2.13, 95%CI: 1.18–3.82, P = 0.01), 
but not depressive symptoms assessed 3 months after stroke (OR: 1.53, 95%CI: 0.86–2.73, P = 0.14).
In the second sub-analysis, we included only patients in whom CRP level was measured within 24 h after 
stroke onset (N = 292). Compared to patients with lower depressive symptoms, patients with greater depres-
sive symptoms at day 8 (median: 9.2, interquartiles: 2.5–17.2 mg/L vs median: 4.3, interquartiles: 2.1–10.3 mg/L, 
Figure 1. Flow chart showing the numbers of patients included in the study and the reasons for non-inclusion 
of excluded patients. NIHSS: National Institute of Health Stroke Scale.
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P < 0.01) had higher CRP level. CRP level did not differ (P = 0.15) between patients who had greater depressive 
symptoms 3 months after stroke (median: 6.7, interquartiles: 2.5–11.2 mg/L) compared to patients who had lower 
depressive symptoms (median: 3.9, interquartiles: 2.1–11.0 mg/L). In the univariate analysis, serum CRP level 
above 9.17 mg/L was associated with higher depressive symptoms at day 8 (OR: 2.49, 95%CI: 1.45–4.29, P < 0.01) 
and CRP level above 6.7 mg/dL was associated with higher depressive symptoms 3 months after stroke (OR: 2.81, 
95%CI: 0.99–3.31, P = 0.05). In the multivariate analysis, higher CRP level remained an independent predictor 
of depressive symptoms at day 8 (OR: 2.89, 95%CI: 1.47–5.69, P < 0.01), but not depressive symptoms assessed 3 
months after stroke (OR: 1.21, 95%CI: 0.56–2.60, P = 0.62).
Discussion
Our study revealed that higher levels of CRP are associated with greater depressive symptoms at day 8 after stroke, 
but their effects on depressive symptoms 3 months after stroke are less significant.
A few studies have examined the relationship between circulating CRP and risk of post-stroke depression. 
These studies yielded conflicting results. Jimenez et al. measured the serum CRP level in 134 patients with 
first-ever ischemic stroke27. Blood was collected at discharge (day 7 ± 2) and 1 month after stroke. About 19% 
of patients were diagnosed as having major depression at discharge according to DSM-IV criteria and 22% of 
patients had major depression 1 month after stroke. The authors did not find any association between CRP level 
and the risk of post-stroke depression. The study of Yang et al. included 226 ischemic stroke patients28. CRP level 
was measured within 24 h after stroke onset. Six months after stroke major depression was diagnosed in 30.5% 
of patients. In this study, serum CRP level above 0.85 mg/dL was associated with the increased risk of depression 
after adjusting for potential confounders. Similarly, Cheng et al. found that higher CRP level measured with 24 h 
after stroke onset predicts the increased risk of depression 1 year after stroke29.
The contribution of inflammatory factors to the pathogenesis of post-stroke depressive symptoms might be 
dependent on time after stroke. Depressive symptoms that occur very early after stroke onset could be a part of 
so-called sickness behaviour. Sickness behaviour is a set of behavioural and motivational changes triggered by 
acute infection or tissue injury and includes anhedonia, hyperalgesia, fever, anorexia, sleepiness, anxiety, and 
disinterest in social interactions30,31. Animal studies have demonstrated that systemic inflammation might induce 
both sickness behaviour and depressive-like symptoms30. Multiple symptoms, for example weight loss, anorexia, 
fatigue, hyperalgesia, anhedonia, anxiety, and neurocognitive symptoms are shared by both sickness behaviour 
and depression. Clinical studies involving cancer patients treated with interferon-alpha (INFα) shed light on 
cytokine-induced sickness behaviour and depressive symptoms. These studies have shown that somatic and 
High score of depressive 
symptoms (N = 104)
Low score of depressive 
symptoms (N = 301) P value
Age, median (IQs) 73 (61–82) 69 (61–80) 0.20
Female, n (%) 68 (65.4) 141 (46.8) <0.01
Hypertension, n (%) 81 (77.9) 204 (67.8) 0.05
Diabetes mellitus, n (%) 33 (31.7) 73 (24.2) 0.13
Atrial fibrillation, n (%) 24 (23.1) 48 (15.9) 0.10
Myocardial infarction, n (%) 17 (16.3) 40 (13.3) 0.44
Previous stroke or TIA, n (%) 27 (26.0) 44 (14.6) <0.01
Pre-stroke dependency, n (%) 11 (10.6) 19 (6.3) 0.15
Pre-stroke cognitive decline, n (%)* 21/87 (24.1) 33/249 (13.2) 0.02
Pre-stroke total NPI score, median 
(IQs)** 4.5 (0–14.5) 0 (0–6) <0.01
Pre-stroke NPI score for 
depression, median (IQs)** 0 (0–2) 0 (0–0) <0.01
Pre-stroke use of antidepressants 6 (5.8) 4 (1.3) 0.01
NIHSS score on admission, n (%) 4 (2–9) 4 (2–9) 0.90
Pneumonia, n (%) 8 (7.7) 16 (5.3) 0.38
Urinary tract infections, n (%) 33 (31.7) 82 (27.2) 0.52
Delirium, n (%) 22 (21.1) 49 (16.3) 0.26
Stroke location, n (%) 0.07
Right hemisphere 53 (51.0) 129 (42.9)
Left hemisphere 35 (33.6) 132 (43.8)
Posterior fossa 11 (10.6) 37 (12.3)
Multiple locations 5 (4.8) 3 (1.0)
Intravenous thrombolysis, n (%) 22 (21.1) 82 (27.2) 0.22
Mechanical thrombectomy, n (%) 6 (5.8) 17 (5.6) 0.96
CRP (mg/L),median (IQs) 7.9 (2.4–20.5) 4.3 (2.1–10.8) <0.01
Table 1. Baseline characteristics of patients with high and patients with low depressive symptoms score at day 
8. *Data available for 336 patients. **Data available for 333 patients.
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vegetative symptoms appeared within 2 weeks of INFα therapy32. In contrast, mood and cognitive symptoms 
appeared later during INFα therapy and were more apparent in patients who developed major depression. The 
hypothesis that early-onset post-stroke depressive symptoms might be related to sickness behaviour is supported 
by the observation that stroke patients with early-onset (in-hospital) depression had higher frequency of vege-
tative (anxiety, loss of energy, morning depression, early awakening, weight loss) and melancholic (loss of inter-
est, depressed mood, psychomotor retardation) symptoms compared to patients with late-onset depression33. 
Alternatively, early-onset post-stroke depression might represent a specific phenotype of depression with dom-
inant somatic (vegetative) symptoms rather than sickness behaviour. Further studies with dimensional analyses 
of specific clusters of neuropsychiatric and somatic symptoms are needed to better characterize the relationship 
between sickness behaviour and post-stroke depressive symptoms. Differentiation of early depressive symptoms 
related to sickness behaviour from those predicting major depression could have therapeutic implications. In 
patients treated with INFα, mood and cognitive symptoms were more responsive, whereas vegetative symptoms, 
such as anorexia or fatigue, were less responsive to paroxetine treatment32.
In the univariate analysis, higher CRP was associated with greater depressive symptoms 3 months after stroke. 
This association was, however, non-significant after adjusting for potential confounders. Inflammatory markers 
decline gradually after stroke13. For this reason, the remote effect of inflammation on depressive symptoms could 
be weaker than in the acute phase of the stroke. Moreover, the persistence of depressive symptoms beyond the 
acute phase of stroke might require additional vulnerabilities, including unresolved inflammation, genetic predis-
position, or alteration in neuronal networks responsible for mood regulation. We cannot exclude the possibility 
that our study had too low statistical power to detect an association between CRP and depressive symptoms 
occurring 3 months after stroke. It should also be noted that inflammatory markers might be selectively associ-
ated with only specific dimensions of depression. In MDD, circulating inflammatory markers are especially linked 
to atypical depression characterized by increased appetite and weight gain34.
There are several limitations to our study. First, the PROPOLIS was designed to determine frequency, pre-
dictors and clinical consequences of post-stroke delirium. Depressive symptoms were considered as a secondary 
end-point of the study and statistical power was not calculated a priori to check if the study was able to detect 
an association between CRP and depressive symptoms. Second, no formal psychiatric diagnosis of depression 
was made. Instead, we used a validated questionnaire to assess depressive symptoms. Third, the CRP level was 
measured only once. Repeated measurements of inflammatory parameters at different time points after stroke 
could give better insight into relationships between inflammation and depression. Fourth, about 27% of patients 
High score of depressive 
symptoms (N = 82)
Low score of depressive 
symptoms (N = 224) P value
Age, median (IQs) 70.5 (63–78) 68 (60–79) 0.30
Female, n (%) 47 (57.3) 108 (48.2) 0.16
Hypertension, n (%) 68 (82.9) 150 (67.0) 0.01
Diabetes mellitus, n (%) 34 (41.5) 49 (21.9) <0.01
Atrial fibrillation, n (%) 16 (19.5) 40 (17.9) 0.74
Myocardial infarction, n (%) 12 (14.6) 30 (13.4) 0.78
Previous stroke or TIA, n (%) 16 (19.5) 38 (17.0) 0.20
Pre-stroke dependency, n (%) 8 (9.8) 12 (5.4) 0.17
Pre-stroke cognitive decline, n (%) 13/67 (19.4) 22/191 (11.5) 0.10
Pre-stroke total NPI score, median 
(IQs) ** 3.5 (0–12) 1 (0–7) 0.03
Pre-stroke NPI score for depression, 
median (IQs)** 0 (0–0) 0 (0–0) 0.94
Pre-stroke use of antidepressants 3 (3.7) 2 (0.9) 0.09
NIHSS score on admission, n (%) 5 (2–10) 4 (2–8) 0.07
Pneumonia, n (%) 8 (9.8) 12 (5.4) 0.17
Urinary tract infections, n (%) 28 (34.1) 52 (23.2) 0.06
Delirium, n (%) 22 (26.8) 27 (12.0) <0.01
Stroke location, n (%) 0.57
Right hemisphere 39 (47.6) 83 (37.0)
Left hemisphere 33 (40.2) 110 (49.2)
Posterior fossa 9 (11.0) 29 (12.9)
Multiple locations 1 (1.2) 2 (0.9)
Intravenous thrombolysis, n (%) 26 (31.7) 59 (26.3) 0.35
Mechanical thrombectomy, n (%) 7 (8.5) 15 (6.7) 0.58
Use of anti-depressants 3 months 
after stroke 19 (23.2) 22 (9.8) <0.01
CRP (mg/L),median (IQs) 6.7 (2.5–18.1) 3.4 (1.9–10.0) 0.01
Table 2. Baseline characteristics of patients with high and patients with low depressive symptoms score at day 
90. *Data available for 258 patients. **Data available for 255 patients.
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who were examined in acute stroke did not attend a control visit. These patients were older and had a more severe 
neurological deficit on admission. Fifth, about 13% of our patients took anti-depressants 3 months after stroke. 
CRP can interact with anti-depressive medication. In MDD patients, the elevated CRP level was associated with 
treatment resistance35.
There are also some advantages to our work. These include the prospective design of the study and assessment 
of pre-stroke psychiatric symptoms and cognitive decline.
Observational studies are not able to demonstrate if an association between CRP and depressive symptoms is 
causative. To verify this association, we need an interventional study that will examine if the anti-inflammatory 
treatment will reduce post-stroke depressive symptoms. From a clinical perspective, depression that occurs early 
after stroke (e.g., during the first 2 weeks after stroke onset) is associated with long-term poor functional out-
come36,37. Thus, anti-inflammatory strategies attenuating systemic inflammatory reaction could have a beneficial 
effect on stroke outcome.
In conclusion, higher levels of serum CRP are associated with early depressive symptoms after ischemic stroke.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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